Nanometer composite particle coated with cell membrane as well as preparation method and application of nanometer composite particle

By designing nanocomposite particles, using membrane structure, piezoelectric materials and magnetic responsive materials, combined with external magnetic field stimulation, the problem of Th1 to Th2 transformation was solved, the polarization and proliferation of Th2 cells were achieved, and T-cell-mediated autoimmunity was alleviated. Reaction, used to treat gastrointestinal inflammation.

CN118924699APending Publication Date: 2024-11-12PEKING UNIV SCHOOL OF STOMATOLOGY
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411321601.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-23
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing technology has failed to effectively achieve the stable conversion of Th1 to Th2, resulting in a lack of effective treatment strategies for patients with autoimmune diseases, and it is not yet clear how CD4+ T cells regulate autoimmune diseases in response to magnetic fields and external magnetic fields.

Method used

Design a nanocomposite particle, including the outer layer of the membrane structure, the intermediate layer of the piezoelectric material and the nuclear structure of the magnetic responsive material. The surface of the membrane structure contains protein molecules that target T cells, regulate Th1/Th2 equilibrium through external magnetic field stimulation, and promote Th2 Cell polarization and alleviates T-cell-mediated autoimmune response.

Benefits of technology

Through contact with cells by nanocomposite particles and under external magnetic field stimulation, Th1/Th2 balance is successfully regulated, Th2 cells are promoted, and the autoimmune response is alleviated. It is used to treat digestive tract inflammation and maintain host immune homeostasis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924699A_ABST
    Figure CN118924699A_ABST
Patent Text Reader

Abstract

The invention discloses a nano-composite particle coated with a cell membrane as well as a preparation method and application of the nano-composite particle. The nano composite particle sequentially comprises a membrane structure outer layer, a piezoelectric material middle layer and a magnetic response material core structure from outside to inside, the outer surface of the membrane structure contains protein molecules, and the protein molecules can target T cells. Under the stimulation of an external magnetic field, the nano-composite particle can regulate Th1 / Th2 balance, promote Th2 cell polarization and enhance T cell proliferation, so that T cell mediated autoimmune response is relieved, host immune homeostasis is maintained, and the nano-composite particle has a wide application prospect in treatment of digestive tract inflammation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and particularly relates to a cell membrane-coated nano composite particle and a preparation method and application thereof. Background Art

[0002] T helper cells can polarize into Th1 and Th2 subsets under various conditions. Unlike the pathogenic role of the Th1 subset in chronic autoimmune diseases such as gastrointestinal inflammation, diabetes, multiple sclerosis, and rheumatoid arthritis, Th2 cells are protective. Therefore, a successful deviation from a Th1-dominant response to a Th2-dominant response may have clinical benefits for patients with autoimmune diseases. However, there is no particularly effective therapeutic strategy to achieve a stable conversion of Th1 to Th2 in vivo.

[0003] Magnetic fields are essential factors for many physiological processes in living organisms. + How T cells respond to magnetic fields and whether external magnetic fields can modulate T cell-mediated autoimmune diseases remain largely unknown.

[0004] The information in the background technology is only for illustrating the general background of the present invention and should not be regarded as admitting or suggesting in any form that such information constitutes the prior art known to a person skilled in the art. Summary of the invention

[0005] In order to solve at least some of the technical problems in the above-mentioned prior art, the present invention constructs a nanocomposite particle which includes, from the outside to the inside, an outer layer of a membrane structure, an intermediate layer of a piezoelectric material, and a core structure of a magnetic response material, and the outer surface of the membrane structure contains protein molecules targeting T cells. The nanocomposite particle of the present invention can adjust the Th1 / Th2 balance and reduce the autoimmune response mediated by T cells, thereby treating gastrointestinal inflammation. Specifically, the present invention includes the following contents.

[0006] According to a first aspect of the present invention, there is provided a nanocomposite particle, which comprises, from the outside to the inside, an outer layer of a membrane structure, an intermediate layer of a piezoelectric material, and a core structure of a magnetic response material, wherein the outer surface of the membrane structure contains protein molecules.

[0007] In certain embodiments, according to the nanocomposite particle of the present invention, the membrane structure is derived from a biological membrane or an artificially synthesized membrane structure.

[0008] In certain embodiments, according to the nanocomposite particle of the present invention, the protein molecule is a binding molecule capable of binding to the surface of T cells.

[0009] In certain embodiments, according to the nanocomposite particles of the present invention, the T cell surface comprises at least one of the following antigens: CD1, CD2, CD3, CD5, CD7, CD8, CD16, CD25, CD26, CD27, CD28, CD30, CD38, CD39, CD40L, CD44, CD45, CD62L, CD69, CD73, CD80, CD83, CD86, CD95, CD103, CD119, CD126, C D150, CD153, CD154, CD161, CD183, CD223, CD254, CD275, CD45RA, CXCR3, CXCR5, FasL, IL18R1, CTLA-4, OX40, GITR, LAG3, ICOS, PD-1, leu-12, TCR, TLR1, TLR2, TLR3, TLR4, TLR6, NKG2D, CCR, CCR1, CCR2, CCR4, CCR6 and CCR7.

[0010] In certain embodiments, according to the nanocomposite particles of the present invention, the protein molecule is capable of targeting CD4 + MHC II complex of T cells.

[0011] In certain embodiments, according to the nanocomposite particle of the present invention, the membrane structure is a cell membrane isolated from an immune cell.

[0012] In certain embodiments, according to the nanocomposite particle of the present invention, the cell membrane comprises a cell membrane isolated from a dendritic cell, a B lymphocyte and / or a macrophage.

[0013] In certain embodiments, according to the nanocomposite particles described in the present invention, the piezoelectric material is selected from at least one of ferrite, niolate, titanate, silicate and aluminate materials, and / or is selected from at least one of polyvinylidene fluoride, polyesters, polymethyl methacrylate, nylon, polyvinyl chloride, poly-L-lactide, poly(3-hydroxybutyrate-co-3-hydroxyvalerate), vinylidene fluoride / trifluoroethylene copolymer, vinylidene fluoride / tetrafluoroethylene copolymer, polyvinylidene fluoride-hexafluoropropylene and polydimethylsiloxane materials; and the magnetic response material is selected from ferrite materials.

[0014] A second aspect of the present invention provides a method for preparing nanocomposite particles, comprising:

[0015] (1) preparing magnetoelectric nanoparticles, wherein the magnetoelectric nanoparticles comprise a piezoelectric material intermediate layer and a core structure of a magnetically responsive material;

[0016] (2) The magnetoelectric nanoparticles are encapsulated in a membrane material, wherein the outer surface of the membrane material contains protein molecules.

[0017] The third aspect of the present invention provides use of nanocomposite particles in preparing a drug for treating digestive tract inflammation, wherein the nanocomposite particles are the nanocomposite particles described in the first aspect of the present invention.

[0018] A fourth aspect of the present invention provides a method for regulating Th1 / Th2 cell balance in vitro, comprising the step of contacting the nanocomposite particles of the present invention with isolated cells in the presence of a magnetic field of 0.01-300 mT.

[0019] The nanocomposite particles of the present invention can adjust the Th1 / Th2 balance, promote Th2 cell polarization and enhance T cell proliferation under the stimulation of an external magnetic field, thereby reducing T cell-mediated autoimmune reactions and maintaining host immune homeostasis, and can be used to treat digestive tract inflammation. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 The preparation and characterization of DC@CFO / BFO nanocomposite particles are shown, where a is a representative SEM image of CFO / BFO nanoparticles; b is a representative high-resolution transmission electron microscope image of CFO / BFO nanoparticles; c is a high-angle annular dark field (HAADF) and corresponding energy dispersive spectroscopy (EDS) elemental mapping image of CFO / BFO nanoparticles; d is a vibrating sample magnetometer (VSM) analysis of CFO / BFO nanocomposite particles; e is a piezoelectric response amplitude curve and phase curve of CFO / BFO nanocomposite particles; f and g are free radicals ·OH and ·O2 generated by CFO / BFO nanocomposite particles under a magnetic field load of 1.5 mT, respectively. - h is a schematic diagram of the preparation of DC@CFO / BFO nanocomposite particles; i is a representative high-resolution transmission electron microscopy image of DC@CFO / BFO nanocomposite particles; j is an immunoblot analysis of surface proteins of DC@CFO / BFO nanocomposite particles, measuring cell membrane-associated proteins (CD11b, β-catenin) and nuclear proteins (HDAC1); k is a nanoflow cytometry analysis (NanoFCM) of the expression levels of CD11c and MHC II on the surface of DC@CFO / BFO nanocomposite particles.

[0021] Figure 2 The in vivo targeting and safety evaluation of DC@CFO / BFO nanocomposite particles are shown, where a and b are the results of combining FITC-conjugated CFO / BFO nanoparticles or DC@CFO / BFO nanocomposite particles (10 μg / mL) with mouse naive CD4 +T cells were incubated and FITC was detected by flow cytometry + Cells and mean fluorescence intensity (MFI); c FITC-conjugated CFO / BFO nanoparticles or DC@CFO / BFO nanocomposite particles (10 μg / mL) were incubated with mouse spleen cells for 12 h, and FITC was detected by flow cytometry + cells; di is the administration of 50 mg / kg of DC@CFO / BFO nanocomposite particles to C57BL / 6 mice by intravenous injection, and magnetic field stimulation (1.5 mT) was performed for 30 minutes every day. Seven days after the injection, the mouse serum was collected and blood biochemical tests were performed; j is the administration of 50 mg / kg of DC@CFO / BFO nanocomposite particles to C57BL / 6 mice by intravenous injection, and magnetic field stimulation (1.5 mT) was used for 30 minutes every day. Seven days after the injection, the main organs of the mice were collected and representative H&E (hematoxylin-eosin) staining images are shown. The scale bar is 100 μm.

[0022] Figure 3 The results show that DC@CFO / BFO nanocomposite particles promote Th2 cell polarization and proliferation under external magnetic field stimulation, where ae is a naive T cell (CD4 + CD25 - CD62L hi CD44 lo ) were activated with plate-bound anti-CD3 and anti-CD28 antibodies, cultured under various polarization conditions with or without DC@CFO / BFO nanocomposite particles and magnetic field treatment, and then stimulated with PMA and ionomycin for 5 h; f is flow cytometric analysis of IFNγ, IL4, IL17A, FOXP3, and CD25 staining in naive T cells (to assess differentiation efficiency), which were activated with plate-bound anti-CD3 and anti-CD28 antibodies, cultured under various polarization conditions with or without DC@CFO / BFO nanocomposite particles and magnetic field treatment, and then stimulated with PMA and ionomycin for 5 h; f is CD4 activated with anti-CD3 / CD28 antibodies + T cells were induced to differentiate into Th2 cells, and then these cells were treated with DC@CFO / BFO nanocomposite particles in the presence or absence of magnetic field stimulation to obtain CD4 + Heat map of genes expressed in T cells related to “Th2 cell differentiation”; g and h are CD4 activated by anti-CD3 / CD28 antibodies + T cells and induced them to differentiate into Th2 cells, and then these cells were treated with DC@CFO / BFO nanocomposite particles in the presence or absence of magnetic field stimulation to perform CD4 + CFSE dilution staining and flow cytometric analysis of Ki-67 expression in T cells.

[0023] Figure 4Transcription analysis of T cells treated with DC@CFO / BFO nanocomposite particles and stimulated by magnetic field, where a is the CD4 + Principal component analysis of T cell transcripts; b CD4 + Heat map of gene expression of T cells; c is the volcano plot analysis of pairwise comparison of transcriptional analysis between DC@CFO / BFO+M group and DC@CFO / BFO group.

[0024] Figure 5 Figure 3 shows the inhibition of T cell transfer-induced colitis by magnetoelectric nanoparticles under external magnetic field stimulation, where a is a schematic diagram of DC@CFO / BFO nanoparticle treatment in a T cell transfer-induced colitis mouse model; b is the weekly assessment of the body weight of mice from different treatment groups; c and d are the gross assessment and length of the colon of mice from different treatment groups on day 42, respectively; e is a representative H&E staining image of colon tissue from mice from different treatment groups on day 42, with a scale bar of 200 μm; f and g are the CD4 + IFNγ + Cells and CD4 + IL4 + Flow cytometric analysis of the proportion of CD4 + IFNγ + Cells and CD4 + IL4 + a) Flow cytometric analysis of the ratio of cells; jm) ELISA to detect inflammatory cytokines in mouse serum.

[0025] Figure 6 CD4 + Flow cytometry analysis results of T subsets, where a is the CD4 + Flow cytometric analysis of the proportion of T cells; b is the CD4 + Flow cytometric analysis of T cell proportion; c and d are CD4 + IL17A + Flow cytometric analysis of cell ratios.

[0026] Figure 7The results show that Th2 cells treated with magnetoelectric nanoparticles inhibited colitis in mice, wherein a is a schematic diagram of the administration of Th2 cells pretreated with DC@CFO / BFO nanoparticles in the T cell transfer-induced colitis mouse model; b is the body weight of mice from different treatment groups evaluated weekly; c is the length of the colon of mice from different treatment groups on day 42; d is a representative H&E staining image of colon tissue of mice from different treatment groups on day 42, with a scale bar of 200 μm. DETAILED DESCRIPTION

[0027] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0028] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that the upper and lower limits of the scope and each intermediate value therebetween are specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0029] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as commonly understood by those skilled in the art to which the invention belongs. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials related to the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0030] Nanocomposite particles

[0031] One aspect of the present invention provides a nanocomposite particle, which includes, from the outside to the inside, an outer layer of a membrane structure, an intermediate layer of a piezoelectric material, and a core structure of a magnetic response material, wherein the outer surface of the membrane structure contains protein molecules.

[0032] In the present invention, the source of the membrane structure is not particularly limited, as long as its surface contains protein molecules that can bind to the surface of T cells. Examples of membrane structures include, but are not limited to, naturally occurring biological membranes or artificially synthesized membrane structures. In a preferred embodiment, the biological membrane is a cell membrane separated from immune cells, examples of which include, but are not limited to, a cell membrane separated from dendritic cells, B lymphocytes or macrophages. In a preferred embodiment, the biological membrane is a cell membrane of dendritic cells.

[0033] In the present invention, the T cell surface contains at least one of the following antigens: CD1, CD2, CD3, CD5, CD7, CD8, CD16, CD25, CD26, CD27, CD28, CD30, CD38, CD39, CD40L, CD44, CD45, CD62L, CD69, CD73, CD80, CD83, CD86, CD95, CD103, CD119, CD126, CD150, CD153, CD154, CD161, CD183, CD223, CD254, CD275, CD45RA, CXCR3, CXCR5, FasL, IL18R1, CTLA-4, OX40, GITR, L AG3, ICOS, PD-1, leu-12, TCR, TLR1, TLR2, TLR3, TLR4, TLR6, NKG2D, CCR, CCR1, CCR2, CCR4, CCR6 and CCR7.

[0034] Those skilled in the art are familiar with how to make the outer surface of the cell membrane contain or express a protein that can target and bind to CD4 + In a preferred embodiment, the protein molecule is a protein molecule that can target CD4 + MHC II complex of T cells.

[0035] In the present invention, the piezoelectric material is selected from at least one of ferrite, niolate, titanate, silicate and aluminate materials, and / or selected from at least one of polyvinylidene fluoride, polyester, polymethyl methacrylate, nylon, polyvinyl chloride, poly-L-lactide, poly(3-hydroxybutyrate-co-3-hydroxyvalerate), vinylidene fluoride / trifluoroethylene copolymer, vinylidene fluoride / tetrafluoroethylene copolymer, polyvinylidene fluoride-hexafluoropropylene and polydimethylsiloxane materials. In a preferred embodiment, the piezoelectric material intermediate layer is bismuth ferrite.

[0036] In the present invention, the magnetic response material is selected from ferrite materials, and the ferrite materials have the following structure: N a Fe 1-a O b , N includes at least one of Co, Mn, Zn and Ni, a is a number ranging from 0.25 to 0.75, and b is 3. In a preferred embodiment, the core structure of the magnetic responsive material is cobalt ferrite.

[0037] It is understood that the magnetoelectric nanoparticles of the present invention may or may not contain doped elements. When doped elements are contained, the doped elements include but are not limited to at least one of carbon, nitrogen, phosphorus, sulfur, silicon, aluminum, iron, titanium, nickel, manganese, copper, silver and zinc, so as to improve the piezoelectric properties and / or magnetic response properties of the magnetoelectric nanoparticles.

[0038] In the present invention, the size of the nanocomposite particles is 100-500nm, preferably 100-450nm, also preferably 100-400nm, further preferably 100-350nm, more preferably 100-300nm, more preferably 100-250nm, for example 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250nm.

[0039] Preparation method

[0040] One aspect of the present invention provides a method for preparing nanocomposite particles, comprising:

[0041] (1) preparing magnetoelectric nanoparticles, wherein the magnetoelectric nanoparticles comprise a piezoelectric material intermediate layer and a core structure of a magnetically responsive material;

[0042] (2) The magnetoelectric nanoparticles are encapsulated in a membrane material, wherein the outer surface of the membrane material contains protein molecules.

[0043] Step (1) of the present invention is to prepare the core structure of the magnetic response material and the piezoelectric material intermediate layer. In a preferred embodiment, the preparation of the core structure of the magnetic response material in step (1) of the present invention comprises: dissolving FeCl3, CoCl2 and CTAB in deionized water, wherein the molar ratio of FeCl3, CoCl2 and CTAB is (2-6):1:(3-9), preferably (2-5):1:(3-8), and further preferably (2-4):1:(3-6), for example, 2:1:3, 2:1:4, 2:1:5, 2:1:6, 3:1:3, 3:1:4, 3:1:5, 3:1:6, 4:1:3, 4:1:4, 4:1:5, 4:1:6, and then, adding NaOH to the above solution under stirring and ultrasonic dispersion, wherein the molar ratio of FeCl3 to NaOH is 1:1. : (20-100), preferably 1: (30-90), more preferably 1: (40-80), for example 1:40, 1:45, 1:50, 1:55, 1:60, 1:65, 1:70, 1:75, 1:80, and then the resulting solution is transferred to a sealed hydrothermal reactor and heated at 150-250°C, preferably 160-240°C, more preferably 170-230°C, for example 170°C, 180°C, 190°C, 200°C, 210°C, 220°C, 230°C for 12-36h, preferably 14-34h, also preferably 16-32h, more preferably 18-30h, for example 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30h. The obtained black powder is then washed with deionized water and ethanol, and then dried overnight at 80-110°C, preferably 85-105°C, and also preferably 90-100°C, such as 90°C, 91°C, 92°C, 93°C, 94°C, 95°C, 96°C, 97°C, 98°C, 99°C, and 100°C to obtain the core structure of the magnetic responsive material, i.e., cobalt ferrite (CFO) nanoparticles.

[0044] In a preferred embodiment, the preparation of the piezoelectric material intermediate layer in step (1) of the present invention includes: dissolving Bi(NO3)·5H2O and Fe(NO3)·9H2O in ethylene glycol to prepare a bismuth ferrite (BFO) precursor, wherein the molar ratio of Bi(NO3)·5H2O and Fe(NO3)·9H2O is (1-5):1, for example 1:1, 2:1, 3:1, 4:1, 5:1.

[0045] To prepare the composite nanoparticles, the dried CFO nanoparticles are dispersed in a BFO precursor solution and sonicated for 1-5 h (e.g., 1, 2, 3, 4, 5 h), wherein the molar ratio of the CFO nanoparticles to the BFO precursor is (1-5):1, e.g., 1:1, 1.5:1, 2:1, 2.5:1, 3:1, 3.5:1, 4:1, 4.5:1, 5:1, and then the solution is dried for 6-20 h, preferably 8-18 h, and further preferably 10-16 h, e.g., 10, 11, 12, 13, 14, 15, 16 h, and then the dried powder is heated at 5-15 ° C / min, preferably 7-13 ° C / min, e.g., 7, 8, 9, 10, 11, 12, 13 ℃ / min, and annealing at 500-700℃, preferably 520-680℃, more preferably 540-660℃, for example 540℃, 550℃, 560℃, 570℃, 580℃, 590℃, 600℃, 610℃, 620℃, 630℃, 640℃, 650℃, 660℃ for 1-5h, for example 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5h, finally, the annealed powder is ultrasonically treated for 15-45min, preferably 20-40min, also preferably 25-35min, for example 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35min and filtered through a filter membrane.

[0046] In certain embodiments, the membrane material described in step (2) of the present invention is an artificially synthesized membrane structure, and the artificially synthesized membrane structure can be prepared by methods known in the art, without particular limitation, examples of which include but are not limited to self-assembly method, template method, charge induction method, etc.

[0047] In certain embodiments, the membrane material in step (2) of the present invention is an isolated cell membrane, which is obtained by cell culture, cell separation and cell lysis.

[0048] In a specific embodiment, the method for preparing a cell membrane comprises: first isolating bone marrow from mouse femur and tibia, and inducing differentiation of dendritic cells (DC) using 10-30 ng / ml, preferably 12-28 ng / ml, and preferably 14-26 ng / ml, such as 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26 ng / ml recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) and 1-20 ng / ml, preferably 2-18 ng / ml, and preferably 4-16 ng / ml, and more preferably 6-14 ng / ml, such as 6, 7, 8, 9, 10, 11, 12, 13, 14 ng / ml recombinant interleukin-4 (IL4), and then sorting DC (CD11c + MHC II + Cells), DCs are lysed by 1-5 (e.g., 1, 2, 3, 4, 5) cycles of freezing and thawing in liquid nitrogen, and the lysate is sonicated for 1-10 min, preferably 2-9 min, further preferably 3-8 min, such as 3, 4, 5, 6, 7, 8 min, to collect cell membranes.

[0049] In a preferred embodiment, step (2) of the present invention comprises continuously passing the membrane material through a 300-500nm, preferably 320-480nm, also preferably 340-460nm, more preferably 360-440nm, for example 360, 370, 380, 390, 400, 410, 420, 430, 440nm porous membrane (for example, a polycarbonate porous membrane), and then extruding the membrane material through a 100-300nm, preferably 120-280nm, also preferably 140-260nm, more preferably 160-240nm, for example 160, 170, 180, 190, 200, 210, 220, 230, 240nm porous membrane to the magnetoelectric nanoparticles obtained in step (1).

[0050] use

[0051] One aspect of the present invention provides use of the nanocomposite particles in preparing a drug for treating digestive tract inflammation.

[0052] The nanocomposite particles of the present invention can promote Th2 cell polarization and enhance T cell proliferation under external magnetic field stimulation, so that T cell-mediated autoimmune reactions can be alleviated, thereby maintaining host immune homeostasis. It is understandable that Th2 cells pretreated with nanocomposite particles or Th2 cells containing nanocomposite particles (cobalt ferrite-bismuth ferrite) are also within the scope of protection of the present invention. Based on this, the present invention further provides the use of Th2 cells pretreated with nanocomposite particles or Th2 cells containing cobalt ferrite-bismuth ferrite in the preparation of a medicament for treating gastrointestinal inflammation.

[0053] In the present invention, digestive tract inflammation is not particularly limited, and examples thereof include but are not limited to gastritis, intestinal inflammation (including but not limited to colon inflammation and rectal inflammation), esophageal inflammation, etc. In a preferred embodiment, digestive tract inflammation is digestive tract inflammation caused by T cells. In a specific embodiment, digestive tract inflammation is colitis.

[0054] In the present invention, external magnetic field stimulation refers to treating the nanocomposite particles under the condition of a magnetic field of 0.01-300 mT. The magnetic field strength is also preferably 0.1-200 mT, further preferably 0.5-100 mT, more preferably 0.5-50 mT, and most preferably 0.5-10 mT, such as 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10 mT. In a preferred embodiment, the magnetic field is applied at a frequency of once a day, 15-30 min each time, for 3 consecutive days at the above magnetic field strength.

[0055] The term "treating" as used herein refers to improving a condition before or after a disease or disorder occurs. This relief is at least 5%, 10%, 20%, 40%, 50%, 60%, 80%, 90%, 95% or 100% as measured by any standard technique compared to an untreated control group under the same conditions. Beneficial or desired clinical results include, but are not limited to, the following, whether detectable or undetectable, including relief of symptoms, reduction in disease severity, stabilization of the disease state (i.e., no worsening), delay or slowing of disease progression, improvement or alleviation of the disease state, and alleviation (whether partial or complete).

[0056] Methods for regulating Th1 / Th2 cell balance in vitro

[0057] In one aspect of the present invention, a method for regulating the balance of Th1 / Th2 cells in vitro is provided, which comprises the step of contacting the nanocomposite particles of the present invention with isolated cells in the presence of a magnetic field of 0.01-300 mT. The isolated cells are T cells, in particular CD4 + T cells.

[0058] The present invention further provides a method for promoting T cell differentiation into Th2 cell subsets in vitro, comprising the step of contacting the nanocomposite particles of the present invention with isolated cells in the presence of a magnetic field of 0.01-300 mT.

[0059] Example 1

[0060] The preparation and performance analysis of DC@CFO / BFO nanocomposite particles are exemplarily shown below.

[0061] 1. Experimental Materials

[0062] CB-17 SCID mice were purchased from Weitong Lihua Laboratory Animal Technology Co., Ltd. All animals were housed and maintained under specific pathogen-free conditions. All animal experiments were performed according to protocols approved by the Ethics Committee of Peking University Health Science Center.

[0063] 2. Preparation method

[0064] 1. Preparation of CFO / BFO

[0065] (1) Preparation of core-structured CFO nanoparticles: 0.092 M FeCl3, 0.046 M CoCl2, and 0.14 M CTAB were dissolved in deionized water. Then, 6 M NaOH was added to the above solution under thorough mechanical stirring and ultrasonic dispersion, and the resulting solution was transferred to a sealed polytetrafluoroethylene hydrothermal reactor and heated at 200 ° C for 24 hours. The black powder was then washed with deionized water and ethanol and then dried at 95 ° C overnight.

[0066] (2) Preparation of core-shell CFO / BFO nanoparticles: 0.011M Bi(NO3)·5H2O and 0.01MFe(NO3)·9H2O were dissolved in ethylene glycol to prepare BFO precursor, and then 0.15g of dried CFO nanoparticles were dispersed into 100mL of BFO precursor solution and ultrasonically treated for 3 hours, and then the solution was dried overnight, and then the dried powder was heated to 600℃ at a heating rate of 10℃ / min and annealed for 2.5 hours. Finally, the annealed powder was ultrasonically treated for 30 minutes and filtered through a 0.22μm filter membrane to obtain magnetoelectric core-shell CFO / BFO nanoparticles.

[0067] 2. Preparation of DC@CFO / BFO Nanocomposite Particles

[0068] Preparation of DC membrane-coated CFO / BFO nanocomposite particles: First, bone marrow from mouse femur and tibia was isolated, and DC differentiation was induced using 20 ng / ml recombinant GM-CSF and 10 ng / ml recombinant IL4. DCs (CD11c+ MHC II + cells), lysed by freezing and thawing in liquid nitrogen for 3 cycles, and the lysate was sonicated for 5 min by a water bath sonicator to collect the cell membranes, which were then continuously extruded through 400 nm and then 200 nm polycarbonate porous membranes onto the magnetoelectric core-shell CFO / BFO nanoparticles to obtain DC@CFO / BFO nanocomposite particles.

[0069] 3. Performance Analysis Method

[0070] 1. Characterization of CFO / BFO Nanoparticles and DC@CFO / BFO Nanocomposite Particles

[0071] The surface morphology of CFO / BFO nanoparticles was characterized by scanning electron microscopy (SEM). The structures of core-shell CFO / BFO nanoparticles and DC film-coated CFO / BFO composites were observed using high-resolution transmission electron microscopy (TEM). The composition of CFO / BFO nanoparticles was determined using energy dispersive X-ray spectroscopy (EDS) spectroscopy or X-ray diffraction spectroscopy with TEM. Piezoelectric response force microscopy (PFM) measurements were recorded by a commercial atomic force microscope equipped with a ferroelectric testing system. The measurements were performed with a vibrating sample magnetometer (VSM). The nanoparticles were placed in ddH2O or DMSO with or without magnetic field stimulation or ultrasonic treatment for ·OH and ·O2 - Detection. 5,5-Dimethyl-1-pyrroline-N-oxide (DMPO) was added to the solution and the reactive species generated by the nanocomposite particles were detected by electron paramagnetic resonance (EPR) technique. The size and surface potential of the nanoparticles were measured by the instrument in an aqueous environment at room temperature.

[0072] 2. Immunoblotting Analysis

[0073] Cells were lysed with RIPA lysis buffer supplemented with a protease inhibitor cocktail and subjected to SDS-PAGE. The antibodies used in this example are as follows: anti-CD11b (abcam, ab133357, 1: 1000), anti-β-catenin (abcam, ab32572, 1: 5000), anti-HDAC1 (Santa Cruz Biotechnology, sc-81598, 1: 1000), anti-puromycin (Merck-millipore, MABE341, 1: 1000) and anti-GAPDH (RayAntibody, RM2002, 1: 5000).

[0074] 3. Sample Preparation and Flow Cytometry Analysis

[0075] Immune cells from spleen or lymph nodes were isolated by grinding the tissue in PBS containing FBS and then filtering through a cell strainer. For lamina propria mononuclear cell (LPMC) isolation, mouse intestines were removed and cut into pieces, then incubated in HBSS containing EDTA. Afterwards, intestinal epithelial cells (IEC) were removed by strong vortexing and passed through a cell strainer, then placed in a digestion solution and slowly rotated. After passing through the filter, lamina propria lymphocytes were isolated by percoll reagent.

[0076] To analyze the surface proteins of DC@CFO / BFO nanocomposite particles, DC@CFO / BFO nanocomposite particles were incubated with specific antibodies at room temperature and analyzed by flow cytometry.

[0077] To detect the cellular uptake of nanoparticles, CFO / BFO nanoparticles and DC@CFO / BFO nanocomposite particles were mixed with the same mass of FITC aqueous solution and then stirred for 12 h. Magnetic separation was performed and washed three times with deionized water to remove excess FITC. FITC-conjugated nanoparticles were incubated with mouse naive T cells or spleen cells, and FITC was detected by flow cytometry. + cell.

[0078] To detect T cell proliferation, isolated T cells were stained with 5% paraformaldehyde at room temperature. Cell activation and proliferation were then induced and collected at the indicated time points for subsequent flow cytometric analysis.

[0079] To analyze cell surface marker expression (CD45, CD4, CD8, CD25, B220, CD11b, Ly6G, CD11c, MHC II, F4 / 80), cells were incubated with specific antibodies at room temperature. To perform intracellular marker staining (IFNγ, IL4, IL17A), cells were treated with a cocktail of protein transport inhibitors, then fixed and permeabilized, followed by staining with specific antibodies. To detect nuclear protein expression (Ki-67, FOXP3), cells were fixed and permeabilized, followed by staining with specific antibodies. The antibodies used included: anti-CD45 (eBioscience, 30-F11), anti-CD4 (BioLegend, GK1.5), anti-CD8 (eBioscience, 53-6.7), anti-CD25 (BioLegend, 3C7), anti-B220 (BioLegend, RA3-6B2), anti-CD11b (BioLegend, M1 / 70), anti-Ly6G (BioLegend, RB6-8C5), anti-CD11c (BioLegend, N418), anti-F4 / 80 (BioLegend, BM8), anti-MHC II (BioLegend, IA / IE)(M5 / 114.15.2), anti-IFNγ (BioLegend, XMG1.2), anti-IL4 (eBioscience, 11B11), anti-IL17A (eBioscience, eBio17B7), anti-Ki-67 (BioLegend, 16A8) and anti-FOXP3 (eBioscience, FJK-16s).

[0080] 4. In vivo imaging of DC@CFO / BFO nanocomposite particles

[0081] To study the in vivo distribution of nanocomposite particles, FITC-labeled DC@CFO / BFO nanocomposite particles (10 mg / kg) were intravenously injected into C57BL / 6 mice. The mouse heart, liver, kidney, lung, and spleen were isolated at the designated time points, and then bioluminescence imaging was performed using an instrument. Images were analyzed using software.

[0082] 5. Biosafety Assessment

[0083] For in vitro cytotoxicity assays, naive mouse CD4 + T cells were exposed to a range of concentrations of nanoparticles for 24 h, and the viability of T cells was assessed by Cell Counting Kit-8.

[0084] For in vivo biosafety assessment, C57BL / 6 mice were administered high concentration (50 mg / kg) of DC@CFO / BFO nanocomposite particles daily and subjected to magnetic field stimulation for 30 minutes. Seven days after injection, blood biochemical and routine blood tests were performed, and histological analysis of major organs was performed.

[0085] 6. In vitro T cell differentiation

[0086] Isolation of mouse naive CD4 from peripheral lymph nodes by flow cytometry + T cells (CD4 + CD25 - CD62L hi CD44 lo ), followed by activation with 2 μg / ml plate-bound anti-CD3 antibody and 1 μg / ml anti-CD28 antibody. For Th1 polarization, 10 μg / mL anti-IL4 antibody and 10 ng / mL of IL-12 were used. For Th2 polarization, 10 μg / mL anti-IFN-γ antibody and 20 ng / mL of IL4 were used. For Th17 polarization, 20 ng / mL of IL-6, 5 ng / mL of TGF-β, 10 μg / mL anti-IFN-γ antibody and 10 μg / mL anti-IL4 antibody were used. For iTreg cell differentiation, 1 ng / mL of TGF-β and 4 ng / mL of IL-2, 10 μg / mL anti-IFN-γ antibody and 10 μg / mL anti-IL4 antibody were used. T cells were incubated with 10 μg / mL of DC@CFO / BFO nanocomposite particles and treated with a 1.5 mT magnetic field for 30 min every day. After 48 or 72 h of culture, the cells were collected for flow cytometry analysis.

[0087] IV. Experimental Results

[0088] 1. Characterization of Cell Membrane-coated Magnetoelectric Nanoparticles

[0089] In this embodiment, nanoscale magnetoelectric materials were synthesized, including a magnetically responsive cobalt (II) ferrite CoFe2O4 (CFO) core and a piezoelectric bismuth (III) ferrite BiFeO3 (BFO) shell (CFO / BFO). The surface morphology and core-shell structure of the CFO / BFO nanocomposite particles were confirmed by scanning electron microscopy and high-resolution transmission electron microscopy. Figure 1 Energy dispersive spectroscopy (EDS) images reveal the uniform distribution of elements in STEM analysis ( Figure 1 c). In addition, vibrating sample magnetometer (VSM) analysis demonstrated the excellent responsiveness of CFO / BFO nanocomposite particles to external magnetic fields, as evaluated by initial magnetization and magnetic saturation intensity ( Figure 1d). PFM reveals detectable localized piezoelectric response hysteresis loops at random locations of the nanoparticles, characterizing their ferroelectric and magnetoelectric properties ( Figure 1 In addition, the oxides (·OH and ·O2) produced in the magneto-electrocatalysis were detected using the EPR spectrum of DMPO. - ), whose signal was observed in CFO / BFO nanocomposite particles under an external magnetic field ( Figure 1 f and g). In addition, due to the piezoelectric properties of BFO, magnetoelectric CFO / BFO nanocomposite particles and BFO nanoparticles can generate ·OH and ·O2 in the presence of exogenous ultrasound. - The characteristic signals of CFO cores were detected, while nanoparticles alone could not trigger the generation of ROS. These findings therefore elucidate the role of magnetic fields in inducing the magnetic response of CFO cores and initiating the potential polarization of BFO shells, thus confirming the effective magnetoelectric conversion.

[0090] To achieve CD4 + T cell targeting specificity, this example selected bone marrow-derived dendritic cells (BMDC) as the research basis, by manipulating their major histocompatibility complex (MHC) II expression, which is related to CD4 + Binding of T cell receptors (TCR) on T cells. Mouse bone marrow cells were first isolated and induced to differentiate into dendritic cells using GM-CSF and IL4. CD11c + MHC II + The cells were subjected to fluorescence activated cell sorting (FACS) and the cell membranes were collected. Then, membrane-coated magnetoelectric nanocomposite particles (DC@CFO / BFO) were prepared by repeated extrusion of the prepared CFO / BFO nanoparticles with freshly extracted BMDC membranes ( Figure 1 h). As shown in TEM, a transparent cell membrane layer of about 10 nm was observed on the surface of the membrane-coated CFO / BFO nanoparticles ( Figure 1 i). Dynamic light scattering experiments showed that the size of the DC@CFO / BFO composites after coating was approximately 170 nm. Zeta potential measurements then showed that the surface charge of the DC@CFO / BFO nanocomposite particles was less negative than that of the CFO / BFO nanoparticles. Subsequent protein blotting and nanoflow cytometry (NanoFCM) analyses confirmed that the DC@CFO / BFO nanocomposite particles displayed surface markers of DC, indicating that native BMDC membranes were successfully translocated and retained onto the CFO / BFO surface ( Figure 1j and k). In addition, by quantifying the glycoprotein, it was found that the glycoprotein content on the DC@CFO / BFO nanocomposite particles was about 90% of the content in the free BMDC membrane, which indicates that the membrane has the correct orientation when coated on the nanoparticles. It can be seen that this example successfully prepared magnetoelectric nanocomposite particles coated with dendritic cell membranes, which exhibited excellent magnetic field responsiveness and magnetoelectric conversion performance.

[0091] 2. Biodistribution characteristics and safety evaluation of DC film-coated magnetoelectric nanoparticles

[0092] First, the standard cell counting kit-8 (CCK-8) was used to measure the initial CD4 + T cells, the cytotoxicity of DC@CFO / BFO nanocomposite particles with or without magnetic field stimulation was evaluated, and it was found that DC@CFO / BFO nanocomposite particles showed good biocompatibility at concentrations below 100 μg / mL. + The high activity of T cells led to the selection of DC@CFO / BFO nanocomposite particles at a concentration of 10 μg / mL for subsequent studies. + T cell uptake of nanocomposite particles. FITC-labeled DC@CFO / BFO or CFO / BFO nanoparticles were co-cultured with naive mouse CD4 + T cells were incubated and the fluorescence signal was assessed by flow cytometry. Figure 2 As shown in a and b, DC membrane coating accelerated T cell phagocytosis of nanocomposite particles, starting at approximately 2 hours and reaching a peak at 8 hours. After 12 hours of co-incubation of particles and mouse spleen cells, most DC@CFO / BFO nanocomposite particles were engulfed by CD4 + T cells, while most naked CFO / BFO nanoparticles were taken up by macrophages ( Figure 2 c). Therefore, these data suggest that encapsulation of DC membranes on CFO / BFO nanoparticles increases their targeting specificity and promotes CD4 + T cell uptake.

[0093] To investigate the biodistribution characteristics of the nanocomposite particles in vivo, FITC-labeled DC@CFO / BFO nanoparticles were administered to C57BL / 6 mice by intravenous injection. In vivo imaging showed that the nanoparticles were enriched in the liver, kidneys, lungs, and spleen and remained in the body for 4 days after injection. Consistent with the low cytotoxicity in vitro, supplementation with high concentrations (50 mg / kg) of DC@CFO / BFO nanocomposite particles with or without magnetic field stimulation had little effect on murine blood cells 7 days after injection. In addition, the effects of DC@CFO / BFO nanocomposite particles on functional parameters of the liver and kidneys were negligible ( Figure 2No significant abnormalities were observed in major organs by histological analysis ( Figure 2 j). Therefore, the data of this example verified the excellent safety of DC@CFO / BFO nanocomposite particles in vivo.

[0094] 3. DC@CFO / BFO nanoparticles promote Th2 cell polarization and proliferation under external magnetic field

[0095] In order to further study the DC@CFO / BFO nanocomposite particles in CD4 + Role in T cell activation and differentiation, activation of CD4 with anti-CD3 and anti-CD28 antibodies under various helper T cell polarization conditions + Flow cytometry analysis showed that in T cells treated with an external magnetic field (DC@CFO / BFO nanocomposite particles), IL4 production was enhanced, while IFN-γ production was reduced, indicating that the combination of magnetoelectric nanocomposite particles and magnetic field promoted Th2 differentiation and inhibited Th1 differentiation ( Figure 3 In addition, T cells produced less IL17A in the DC@CFO / BFO group and the DC@CFO / BFO+M group, and the proportion of induced Treg cells (iTreg) in all groups did not differ significantly ( Figure 3 a, d and e).

[0096] In order to more accurately describe the role of magnetoelectric nanocomposite particles in Th2 polarization, RNA sequencing was performed in this example to analyze the transcriptome of T cells treated with magnetoelectric nanocomposite particles and magnetic fields under Th2 differentiation conditions. Principal component analysis (PCA) and differentially expressed genes (DEGs) analysis showed that activated T cells showed similar gene expression patterns in the absence of magnetic fields in the presence or absence of DC@CFO / BFO nanocomposite particles. However, T cells in the DC@CFO / BFO+M group were clearly distinguished from T cells without magnetoelectric nanoparticles or magnetic field stimulation by their transcripts ( Figure 4 a and b). Subsequent GO enrichment showed that genes related to “DNA replication”, “T cell differentiation”, and “T cell proliferation” were over-represented among the significantly up-regulated genes in T cells under Th2 cell polarization conditions (vector group and DC@CFO / BFO group) relative to naive T cells, indicating favorable T cell polarization induction.

[0097] Subsequently, we analyzed the overall gene expression changes of T cells treated by DC@CFO / BFO in the presence or absence of a magnetic field and found that there were 898 upregulated genes and 1703 downregulated genes in T cells after DC@CFO / BFO+M treatment ( Figure 4c). Consistent with previous data, upregulated genes were enriched in “Type II immune response” and “Th2 cell differentiation” compared with T cells in the DC@CFO / BFO group, reflecting the stimulatory effect of DC@CFO / BFO treatment and concomitant magnetic field stimulation on Th2 cell polarization ( Figure 3 f). In addition, DC@CFO / BFO nanocomposite particles promoted signaling pathways associated with T cell proliferation when loaded with a magnetic field. Subsequent flow cytometry analysis also confirmed that under Th2 cell polarization conditions, CD4 + T cells underwent more cell divisions in response to DC@CFO / BFO+M treatment, as detected by CFSE dilution assay and Ki-67 staining ( Figure 3 g and h). It can be seen that the treatment of magnetoelectric nanocomposite particles combined with magnetic field stimulation promoted the induction of Th2 cell polarization and enhanced the proliferation capacity of T cells in vitro.

[0098] Example 2

[0099] The following uses colitis as an example to illustrate the application of DC@CFO / BFO nanoparticles in gastrointestinal inflammation.

[0100] 1. Experimental Methods

[0101] 1. Colitis T Cell Transfer Model

[0102] Isolation of naive CD4 + CD45RB hi cells and injected intraperitoneally into CB17-SCID recipients (1×10 6 cells). 10 mg / kg of DC@CFO / BFO nanocomposite particles were intravenously injected into mice at the specified time points, and 1.5 mT magnetic field stimulation was applied for 30 minutes every day after nanoparticle injection. The weight change of each mouse was monitored weekly after transfer. When significant weight loss occurred in the experimental group, the mice were killed.

[0103] 2. Enzyme-linked immunosorbent assay (ELISA)

[0104] ELISA for glycoproteins on cell membranes or nanoparticles was performed according to the manufacturer's instructions.

[0105] Type 2 collagen (anti-CII) specific antibodies in sera of immunized mice were measured by ELISA. Serum samples were added to CII pre-coated plates followed by goat anti-mouse IgM, IgG1, IgG2a, IgG2b, IgG3 and IgA.

[0106] 3. Serum inflammatory cytokine detection

[0107] Murine serum samples were collected from mice, and inflammatory cytokines were measured using a mouse cytokine detection kit according to the manufacturer's instructions.

[0108] 4. Histological Analysis

[0109] For H&E staining of mouse colon, the tissue was fixed with formaldehyde and then embedded in paraffin. The sections were used for H&E staining. Images were acquired using a microscope.

[0110] 5. RNA Sequencing

[0111] To investigate the role of magnetoelectric nanocomposite particles in T cell-mediated responses, CD4 + T cells were incubated with magnetoelectric nanocomposite particles and subjected to magnetic field treatment under Th2 differentiation conditions. Total RNA was then purified using poly-T oligonucleotide-linked magnetic beads. RNA-seq libraries were constructed and sequenced using a library preparation kit. High-quality reads were obtained by removing reads containing adapters and poly-N and low-quality reads from the raw data according to the manufacturer's instructions. High-quality reads were aligned to the reference genome Hisat2 based on the gene model annotation file. The fragments per kilobase per million mapped reads (FPKM) were calculated for each gene based on the length of the gene and the read count mapped to the gene. The overlap of gene sets from RNAseq data with curated datasets in MSigDB was analyzed.

[0112] 6. Quantitative Proteomic Analysis

[0113] Isolation of CD4 + T cells were then incubated with magnetoelectric nanocomposite particles under Th2 differentiation conditions, magnetic field treatment, and 100 μg of protein samples from each subject were subjected to LC-MS / MS analysis.

[0114] 7. Non-targeted metabolomics analysis

[0115] Isolation of CD4 + T cells were then incubated with magnetoelectric nanocomposite particles under Th2 differentiation conditions and magnetic field treatment. To extract the metabolites of the T cells, the cell pellets were resuspended in methanol (precooled to -80°C) and frozen in liquid nitrogen. These quenched cells were then thawed and vortexed. Centrifuged, the supernatant was transferred to a new tube and lyophilized under vacuum. The dried samples were then reconstituted in methanol and incubated. The samples were then centrifuged and the supernatant was used for LC-MS / MS analysis.

[0116] 8. Statistical Analysis

[0117] Statistical analysis was performed using software. The differences between the two groups were analyzed using a two-tailed Student's t-test, and P < 0.05 was considered significant.

[0118] 2. Experimental Results

[0119] DC@CFO / BFO nanoparticles inhibit T cell transfer-induced colitis

[0120] In order to further study the anti-inflammatory effect of DC@CFO / BFO+M treatment, this example used CD4 + CD45RB hi Naive T cells were transferred into CB-17SCID mice to induce colon inflammation. During the experiment, recipient mice were administered DC@CFO / BFO nanoparticles and magnetic field treatment ( Figure 5 a). Mice without magnetic field treatment (vehicle and DC@CFO / BFO groups) developed wasting disease associated with severe colitis, whereas DC@CFO / BFO+M treatment significantly ameliorated colitis development, as determined by weight loss and shortened colon length ( Figure 5 Histological analysis showed that attenuated colonic inflammatory damage and less inflammatory cell infiltration were observed in mice treated with DC@CFO / BFO nanocomposite particles and repetitive magnetic field stimulation ( Figure 5 e). Then, immune cells were isolated from the spleen and colon lamina propria, and it was found that the percentage of cells producing IL4 increased in the DC@CFO / BFO+M group mice, while IFNγ + T cells and IL17A + T cell reduction ( Figure 5 fi and Figure 6 Thus, DC@CFO / BFO+M treatment suppressed the protein levels of the indicated inflammatory molecules ( Figure 5 of jm).

[0121] Consistent with the above data, Th2 cell transfer treated with magnetoelectric nanocomposite particles and magnetic field also alleviated colon pathological damage, as determined by weight loss, colon length, and H&E staining ( Figure 7 ad). Therefore, these findings further confirmed that DC@CFO / BFO nanoparticles promoted Th2 polarization in vivo and conferred protection against T cell transfer-induced colitis under magnetic field stimulation.

[0122] Conclusion

[0123] The present invention uses membrane materials to coat magnetoelectric nanoparticles, thereby improving the targeting of magnetoelectric nanoparticles to T cells. Experimental results show that these magnetoelectric nanoparticles coordinate T cell differentiation and proliferation, and improve the host autoimmune response in a mouse T cell transfer-induced colitis model when stimulated by an external magnetic field. It can be seen that the nanocomposite particles of the present invention regulate the Th1 / Th2 balance and promote the proliferation of Th2 cells, thereby improving T cell-mediated autoimmune reactions and maintaining host immune homeostasis.

[0124] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit them; although the present invention has been described in detail with reference to the above embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the above embodiments, or replace some of the technical features therein by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A nanocomposite particle, It is characterized in that From the outside to the inside, it includes an outer layer of a membrane structure, an intermediate layer of a piezoelectric material, and a core structure of a magnetic response material, wherein the outer surface of the membrane structure contains protein molecules.

2. The nanocomposite particles according to claim 1, It is characterized in that The membrane structure is derived from a biological membrane or an artificially synthesized membrane structure.

3. The nanocomposite particles according to claim 1, It is characterized in that The protein molecule is a binding molecule capable of binding to the surface of T cells.

4. The nanocomposite particles according to claim 3, It is characterized in that The T cell surface contains at least one of the following antigens: CD1, CD2, CD3, CD5, CD7, CD8, CD16, CD25, CD26, CD27, CD28, CD30, CD38, CD39, CD40L, CD44, CD45, CD62L, CD69, CD73, CD80, CD83, CD86, CD95, CD103, CD119, CD126, CD150, CD153, CD1 54. CD161, CD183, CD223, CD254, CD275, CD45RA, CXCR3, CXCR5, FasL, IL18R1, CTLA-4, OX40, GITR, LA G3, ICOS, PD-1, leu-12, TCR, TLR1, TLR2, TLR3, TLR4, TLR6, NKG2D, CCR, CCR1, CCR2, CCR4, CCR6 and CCR7.

5. The nanocomposite particles according to claim 1, It is characterized in that The protein molecule is capable of targeting CD4 + MHC II complex of T cells.

6. The nanocomposite particles according to claim 1, It is characterized in that The membrane structure is a cell membrane separated from immune cells.

7. The nanocomposite particles according to claim 6, It is characterized in that The cell membranes include cell membranes isolated from dendritic cells, B lymphocytes and / or macrophages.

8. A method for preparing nanocomposite particles, It is characterized in that include: (1) preparing magnetoelectric nanoparticles, wherein the magnetoelectric nanoparticles comprise a piezoelectric material intermediate layer and a core structure of a magnetically responsive material; (2) The magnetoelectric nanoparticles are encapsulated in a membrane material, wherein the outer surface of the membrane material contains protein molecules.

9. Use of nanocomposite particles in the preparation of drugs for treating digestive tract inflammation, It is characterized in that The nanocomposite particles are the nanocomposite particles according to any one of claims 1 to 7.

10. A method for regulating Th1 / Th2 cell balance in vitro, It is characterized in that The method comprises the step of contacting the nanocomposite particles according to any one of claims 1 to 7 with isolated cells in the presence of a magnetic field of 0.01 to 300 mT.

Citation Information

Patent Citations

  • Application of magnetoelectricity-driven magnetostrictive piezoelectric nanoparticles in antiviral therapy

    CN117919206A

  • Membrane-coated self-assembled nano-drug particle, intermediate, preparation method and application thereof

    CN118557547A

  • Cell membrane-coated nanodecoy capable of clearing proinflammatory factors and inhibiting t cell activation, and preparation method therefor and use thereof

    WO2023134122A1

  • KR20240036922A